scholarly journals Is early response by 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography a predictor of long-term outcome in patients with metastatic colorectal cancer?

2016 ◽  
Vol 7 (3) ◽  
pp. 365-372 ◽  
Author(s):  
Maria Nirvana da Cruz Formiga ◽  
Marcello Ferretti Fanelli ◽  
Aldo Lourenço Abadde Dettino ◽  
Ulisses Ribaldo Nicolau ◽  
Marcelo Cavicchioli ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Metastatic Colorectal Cancer ◽  
Early Response ◽  
Emission Tomography ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Positron Emission

Detection of recurrent and metastatic colorectal cancer: Comparison of positron emission tomography and computed tomography

1997 ◽  
Vol 4 (8) ◽  
pp. 613-620 ◽  
Author(s):  
Olagunju A. Ogunbiyi ◽  
Fidelma L. Flanagan ◽  
Farrokh Dehdashti ◽  
Barry A. Siegel ◽  
Diane D. Trask ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Metastatic Colorectal Cancer ◽  
Emission Tomography ◽  
Positron Emission

Positron Emission Tomography Combined With Computed Tomography vs. No Positron Emission Tomography Combined With Computed Tomography for the Management of Patients With Resectable Colorectal Cancer Liver Metastases and Synchronous Extrahepatic Disease

2020 ◽  
pp. 000313482095483
Author(s):  
Pablo E. Serrano ◽  
Chu-Shu Gu ◽  
Carol-Anne Moulton ◽  
Steven Gallinger
Keyword(s):  
Colorectal Cancer ◽  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Liver Metastases ◽  
Surgical Management ◽  
Emission Tomography ◽  
Colorectal Cancer Liver Metastases ◽  
Positron Emission ◽  
Pet Ct

Introduction Selected patients with colorectal cancer liver metastases (CRLM) and synchronous extrahepatic disease (EHD) are considered for surgery. Objectives To evaluate the change in surgical management and long-term survival (disease-free survival [DFS] and overall survival [OS]) for patients with CRLM and EHD who undergo positron emission tomography combined with computed tomography (PET-CT) vs no PET-CT. Methods Patients with CRLM were enrolled in a trial evaluating the effect of PET-CT (vs no PET-CT) on surgical management, DFS, and OS. This is a sub-study of the trial, including only patients with synchronous EHD. Cox proportional hazard models were used to calculate risks for recurrence and death. Survival were described by Kaplan-Meier method and compared with log-rank test. Results Of 25 patients with EHD (PET-CT arm: 14/270 (5%) and no PET-CT arm: 11/134 (8%)), PET-CT changed surgical management in 14%, all of which avoided liver resection due to more extensive disease. Complete metastasectomy was achieved in 36% (5/14) and 72% (8/11), respectively. Respectively, PET-CT vs no PET-CT had statistically similar median DFS, 5.6 months (95% confidence interval (CI) 3.6-18) vs 7.6 months (95% CI 2.9-15) and median OS, 42 months (95% CI 25-48) vs 29 months (95% CI 17-41). EHD was associated with worse DFS (hazard ratio HR = 1.89, 95% CI 1.41-2.52) and OS (HR = 2.47, 95% CI 1.6-3.83). Conclusions Preoperative PET-CT for the management of resectable CRLM did not improve long-term outcomes among patients who had synchronous EHD; however, it changed surgical management in a relatively significant proportion of patients.

Sign in / Sign up

Export Citation Format

Share Document